Article

CURE Inaugural Commercial to Air During SU2C Telecast

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight, announced Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of CURE Media Group. The commercial aims to give individuals with cancer a platform to voice how they are more than just patients.

“We are so honored to be recognized during the Stand Up To Cancer (SU2C) telecast,” said Michael J. Hennessy Jr., in making the announcement. “This is a huge achievement for the CURE Media Group and we are so thankful to get our message across airing our first commercial.”

CURE® message, “Today, I’m more than a patient,” will fill millions of screens during SU2C’s sixth biennial televised fundraising special. CURE® hopes viewers will share how they are more than a patient, using the hashtag #MoreThanAPatient on social media.

The commercial will air on CBS in New York, San Francisco and Boston on Friday, Sept. 7 at 8 p.m. ET/PT and 7 p.m. CT.

To see the commercial after it airs, visit http://www.curetoday.com or find us on Twitter @cure_magazine, Facebook @curemagazine or Instagram @curetoday.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.